๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Orbassano
Clinical trial register · Italy

Clinical Trials in Orbassano, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 6830 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:52 UTC
6830
Studies in scope
all four open statuses
4109
Recruiting now
open to new participants
1019
Lead sponsors
across recruiting studies
Top sites
Milan 2849 Bologna 1313 Roma 1277 Naples 984 Rome 980
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca28 Hoffmann-La Roche10 Pfizer7 Merck Sharp & Dohme LLC7 Novartis Pharmaceuticals7
Site location
Milan2849 Bologna1313 Roma1277 Naples984 Rome980
All 483 locations
Target enrolment
to

Trials with a site in Orbassano

153 of 6830 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma
NCT07763171Gastroesophageal Adenocarcinoma
DrugsRamucirumab·Folfox·Tislelizumab·Paclitaxel
Gruppo Oncologico del Nord-Ovest
Phase 3
244
San Giovanni Rotondo, Tricase, Rozzano, Orbassano, Aviano, Bari, Bologna, Crema
2026-09-01
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
Roma, Orbassano, Bergamo
2026-07-02
Recruiting
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031Solid Tumors
DrugsAdagrasib·Leucovorin·Fluorouracil·Cetuximab
Mirati Therapeutics Inc.
Phase 2
170
Rome, Bologna, Florence, Meldola, Milan, Orbassano, Pesaro, Roma
2026-05-06
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Naples, Ravenna, Aviano, Orbassano, Rome, Milan, Parma
2026-03-16
Not yet open
Low VS High-fidelity Interprofessional Simulation for ABG Skills Acquisition
NCT06493188Interprofessional Relations, Self Efficacy, Knowledge, Attitudes, Practice
University of Turin, Italy
Not applicable
36
Orbassano
2026-03-01
Recruiting
Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Hospitalizations
NCT06846879Quality of Care, Evaluation, Emergency Department, Appropriateness
Mario Negri Institute for Pharmacological Research
Observational
240,000
Alessandria, Cuneo, Novara, Novi Ligure, Orbassano, Rivoli, Torino
2026-01-05
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel
Bristol-Myers Squibb
Phase 2/3
590
Naples, Ravenna, Aviano, Orbassano, Siena, Perugia, Bologna, Milan
2026-01-02
Recruiting
A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
NCT07301034Myocardial Infarction
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
332
Rome, Bergamo, Messina, Rivoli, Genova, Novara, Orbassano, San Donato Milanese
2025-12-18
Not yet open
EARLY: Educational Intervention to Improve Patient Awareness on Early LDL-C Lowering in Secondary Prevention
NCT07252388Acute Coronary Syndromes, Chronic Coronary Syndromes
Heart Care Foundation
Not applicable
240
Orbassano, Torino, Acquaviva delle Fonti, Ancona, Arzignano, Benevento, Cagliari, Caserta
2025-12-11
Recruiting
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
NCT07226999Small Cell Lung Cancer (SCLC)
DrugsPF-08634404·Atezolizumab
Pfizer
Phase 2/3
550
Aviano, Roma, Orbassano
2025-12-09
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naรฏve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel
Amgen
Phase 3
750
Foggia, Milan, Modena, Orbassano, Peschiera del Garda, Rozzano, Trento
2025-11-28
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402Renal Cell Carcinoma
DrugsZanzalintinib·Belzutifan·Cabozantinib
Merck Sharp & Dohme LLC
Phase 3
904
Naples, Rome, Milan, Rozzano, Orbassano, Florence, Castelfranco Veneto, Peschiera del Garda
2025-11-26
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab
AbbVie
Phase 2
180
Rome, Orbassano, Roma
2025-11-25
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Milan, Orbassano, Pavia, Roma
2025-11-24
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
Ravenna, Aviano, Orbassano, Candiolo, Avellino, Milan, Naples, Parma
2025-11-05
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDatopotamab Deruxtecan·Docetaxel
AstraZeneca
Phase 3
400
Milan, Monza, Orbassano, Padova, Rozzano
2025-10-31
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Pembrolizumab
Daiichi Sankyo
Phase 3
686
Bologna, Candiolo, Fano, Genova, Livorno, Milan, Misterbianco, Orbassano
2025-10-24
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer
DrugLuxdegalutamide
Novartis Pharmaceuticals
Phase 1/2
188
Milan, Padova, Orbassano
2025-10-15
Active, closed
A New Crowding Indicator in the Emergency Department
NCT07111624Emergency Department, Crowding
Mario Negri Institute for Pharmacological Research
Observational
828
Brescia, Genova, Ravenna, Roma, Ciriรฉ, Orbassano, Vercelli, Alessandria
2025-10-15
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naรฏve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
1,000
Meldola, Ravenna, Rozzano, Orbassano, Rome, Milan, Novara, Padova
2025-09-28
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged โ‰ฅ40 to โ‰ค85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
DrugDupilumab
Sanofi
Phase 4
218
Cona, Giugliano in Campania, Orbassano, Siena
2025-09-22
Recruiting
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865Sickle Cell Disease
DrugRilzabrutinib
Sanofi
Phase 3
192
Florence, Milan, Naples, Rome, Orbassano, Palermo, Verona
2025-08-12
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898Neoplasms, Lung
DrugsRis-Rez·Topotecan
GlaxoSmithKline
Phase 3
420
Bergamo, Genova, Milan, Orbassano, Pisa, Siena, Verona
2025-08-11
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Datopotamab Deruxtecan
AstraZeneca
Phase 2
278
Aviano, Catania, Meldola, Milan, Orbassano, Roma, Rozzano
2025-08-07
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07005102Non-Squamous Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin
AbbVie
Phase 2/3
854
Rome, Orbassano
2025-08-03
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsSigvotatug vedotin·Pembrolizumab
Pfizer
Phase 3
714
Naples, Misterbianco, Meldola, Pesaro (PU), Orbassano, Rome, Roma, Catania
2025-07-23
Active, closed
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556Metastatic Hormone-sensitive Prostate Cancer
DrugsLuxdegalutamide·Abiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 2
168
Asti, Padova, Trento, Orbassano, Verona
2025-07-07
Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272Castration-Resistant Prostatic Cancer, Metastasis
DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide
Merck Sharp & Dohme LLC
Phase 1/2
360
Orbassano, Brescia, Milan, Naples, Roma
2025-07-03
Not yet open
Institution of an Italian Multicenter Database of Patients With Multiple Endocrine Neoplasia Type 1 (MENNET1 Database)
NCT06790251Multiple Endocrine Neoplasia Type 1
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Observational
600
Orbassano, Bari, Bologna, Cagliari, Cuneo, Ferrara, Florence, Genova
2025-06-01
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581Asthma
DrugTilrekimig
Pfizer
Phase 2
252
Monserrato, Reggio Emilia, Rozzano, Orbassano, Siena, Salerno, Torino
2025-05-20
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 3
150
Florence, Orbassano, Roma
2025-05-15
Recruiting
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06747351Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
DrugsTAK-881·Hyqvia
Takeda
Phase 3
59
Milan, Rozzano, Orbassano, Brescia, Genova, Messina, Pavia, Pisa
2025-05-06
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Bari, Meldola, Naples, Orbassano, Rome, Florence, Genova, Padova
2025-04-24
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Bari, Catania, Genova, Meldola, Milan, Monza, Naples, Orbassano
2025-03-27
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Celgene
Phase 3
960
Milan, Orbassano, Rome, Padova, Arezzo, Foggia, Naples, Terni
2025-03-13
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin
AbbVie
Phase 1/2
252
Meldola, Milan, Rome, Orbassano, Ancona, Bologna
2025-03-06
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
780
Rome, Bari, Bergamo, Milan, Orbassano, Parma, Peschiera del Garda
2025-02-27
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268Sickle Cell Disease
DrugEtavopivat
Novo Nordisk A/S
Phase 3
510
Orbassano, Verona, Brescia, Catania, Modena, Monza, Naples, Padova
2025-02-17
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
180
Bergamo, Orbassano, Naples
2025-02-07
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226Sickle Cell Disease, Thalassemia
Novo Nordisk A/S
Phase 3
480
Orbassano, Padova, Pavia
2025-01-10
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 2
480
Orbassano, Padova, Ravenna, Roma, Rozzano
2024-12-16
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide
Amgen
Phase 3
707
Foggia, Gallipoli, Genova, Milan, Orbassano, Trento
2024-12-09
Active, closed
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983Muscle-invasive Urothelial Carcinoma
DrugsAutogene cevumeran·Nivolumab
Hoffmann-La Roche
Phase 2
62
Bari, Rome, Orbassano, Verona
2024-12-09
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245Patients With Non-Small Cell Lung Cancer
DrugsTedopi·Docetaxel
OSE Immunotherapeutics
Phase 3
363
Meldola, San Filippo, Rozzano, Naples, Orbassano, Legnago, Genova, Lecce
2024-12-03
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsDocetaxel·Pembrolizumab
Genmab
Phase 3
191
Monza, Rozzano, Naples, Aviano, Rome, Orbassano, Bergamo, Candiolo
2024-11-25
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel
AstraZeneca
Phase 3
1,160
Florence, Legnano, Livorno, Monza, Orbassano, Padova, Peschiera del Garda, Roma
2024-11-18
Recruiting
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117Solid Tumor, MET Alteration
Pierre Fabre Medicament
Phase 1/2
140
Orbassano
2024-10-22
Recruiting
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06417814Metastatic Non-small Cell Lung Cancer
DrugsTagrisso·Datopotamab Deruxtecan·Osimertinib·Pemetrexed
AstraZeneca
Phase 3
744
Bari, Milan, Misterbianco, Monza, Naples, Orbassano, Padova, Parma
2024-10-04
Recruiting
Development of a Natural Language Processing Tool to Enable Clinical Research in Emergency Medicine
NCT06240572Emergency Medicine
Mario Negri Institute for Pharmacological Research
Observational
300,000
Milan, Catania, Orbassano, Pozzuoli, Torino, Vercelli
2024-10-01
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
Florence, Orbassano, Roma, Verona
2024-09-30
Recruiting
SPAGO: Sirolimus Paclitaxel Angiographic Gain Objective
NCT06373601Coronary Artery Disease, Stenosis Coronary, Coronary Artery Lesion, Percutaneous Coronary Intervention
Fondazione Evidence per Attivitร  e Ricerche Cardiovascolari ONLUS
Not applicable
140
Mercogliano, Bergamo, Brescia, Ferrara, Milan, Rozzano, Naples, Orbassano
2024-09-05
Recruiting
Intracoronary Optical Coherence Tomography Guidance Vs. Angiography Only Guidance for Treatment of Coronary In-stent Restenosis
NCT06779110Coronary Artery Disease, Stent Restenosis, STENT
San Luigi Gonzaga Hospital
Not applicable
360
Aosta, Biella, Cuneo, Cona, Genova, Rivoli, Trapani, Orbassano
2024-09-01
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin
Bayer
Phase 3
555
Avellino, Aviano, Bologna, Florence, Lecce, Meldola, Milan, Orbassano
2024-08-28
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel
AstraZeneca
Phase 2
194
Genoa, Meldola, Milan, Naples, Orbassano, Perugia, Rozzano, Udine
2024-08-27
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·5-FU·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Alessandria, Bergamo, Orbassano
2024-08-22
Recruiting
Preventing Cardiovascular Collapse With Vasopressors During Tracheal Intubation
NCT05014581Critical Illness, Respiratory Failure
DrugNoradrenaline
University of Turin, Italy
Phase 3
420
Rozzano, Orbassano, Milan
2024-08-01
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
146
Bologna, Florence, Genova, Milan, Palermo, Roma, Orbassano
2024-07-31
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
136
Bologna, Milan, Orbassano, Padova, Palermo, Prato, Roma
2024-07-09
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Osimertinib
AstraZeneca
Phase 3
582
Milan, Monza, Orbassano, Padova, Parma
2024-04-29
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naรฏve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
DrugsMomelotinib·Pacritinib·Selinexor·Ruxolitinib
Karyopharm Therapeutics Inc
Phase 2
58
Milan, Orbassano, Torino, Bologna, Genova, Meldola, Novara, Pavia
2024-04-22
Recruiting
Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
NCT06375941Angiosarcoma
Italian Sarcoma Group
Observational
250
Rozzano, Aviano, Orbassano, Bari, Bologna, Florence, Genova, Milan
2024-03-29
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Aviano PN, Milan, Orbassano, Padova, Perugia, Pisa, Reggio Emilia, Rozzano MI
2024-02-20
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsRMC-6291·RMC-9805·RMC-6236·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Meldola, Milan, Orbassano, Ravenna, Rome
2024-01-18
Recruiting
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia
NCT05759299Airway Complication of Anesthesia
University of Turin, Italy
Observational
10,500
Monza, Orbassano, Torino, Milan, Trento
2024-01-15
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Cona, Florence, Genoa, Milan, Monza, Naples, Rome, Orbassano
2023-12-13
Active, closed
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
NCT05988073Multifocal Motor Neuropathy
argenx
Observational
413
Florence, Gussago, Messina, Novara, Orbassano, Palermo, Pavia, Pisa
2023-11-29
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
Verona, Ancona, Aviano, Meldola, Milan, Naples, Orbassano, Ravenna
2023-11-14
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Ipilimumab·Pemetrexed·Nivolumab
AstraZeneca
Phase 3
863
Alessandria, Bari, Bergamo, Milan, Monza, Orbassano, Padova, Parma
2023-11-09
Active, closed
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT06088290Leiomyosarcoma
DrugsLurbinectedin·Doxorubicin
PharmaMar
Phase 3
469
Rozzano, Naples, Aviano, Bologna, Candiolo, Orbassano, Padova, Palermo
2023-09-21
Recruiting
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082Non-Small Cell Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 1/2
320
Naples, Rome, Milan, Orbassano
2023-06-20
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Bergamo, Catanzaro, Genova, Meldola (FC), Orbassano, Roma
2023-05-31
Active, closed
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734Carcinoma, Non-Small-Cell Lung
DrugsCetrelimab·Amivantamab
Janssen Research & Development, LLC
Phase 1/2
71
Milan, Orbassano, Verona
2023-05-18
Recruiting
INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations
NCT06334809Prostate Cancer
Fondazione del Piemonte per l'Oncologia
Observational
400
Candiolo, Orbassano
2023-03-09
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Pemetrexed·Keytruda·Cisplatin
Daiichi Sankyo
Phase 3
1,170
Candiolo, Lucca, Orbassano, Rome, Udine, Varese, Verona
2023-01-11
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
DrugsDatopotamab Deruxtecan·Durvalumab·Pemetrexed·Paclitaxel
AstraZeneca
Phase 3
1,350
Florence, Lecco, Messina, Naples, Orbassano, Padova, Parma, Peschiera del Garda
2022-12-29
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·5-FU·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
Milan, Orbassano, Rozzano, Verona
2022-12-21
Active, closed
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (ฮฑ)-Thalassemia
NCT05664737Anemia
DrugLuspatercept
Bristol-Myers Squibb
Phase 2
189
Genova, Orbassano, Naples
2022-12-09
Active, closed
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression โ‰ฅ 1% and an STK11 Co-mutation.
NCT05445843Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression โ‰ฅ 1% and an STK11 Co-mutation
DrugJDQ443
Novartis Pharmaceuticals
Phase 2
95
Bari, Rozzano, Roma, Orbassano
2022-12-06
Active, closed
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183Cystic Fibrosis
DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor
Vertex Pharmaceuticals Incorporated
Phase 3
297
Ancona, Florence, Genova, Messina, Milan, Naples, Orbassano, Potenza
2022-11-23
Active, closed
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578Advanced NSCLC, Metastatic Lung Cancer
DrugAdagrasib
Mirati Therapeutics Inc.
Phase 2
90
Avellino, Casale Monferrato, Florence, Milan, Orbassano, Ravenna, Roma
2022-11-22
Active, closed
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257Cystic Fibrosis
DrugVNZ/TEZ/D-IVA
Vertex Pharmaceuticals Incorporated
Phase 3
822
Ancona, Florence, Genova, Milan, Orbassano, Potenza, Verona
2022-11-08
Recruiting
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
NCT05363319Non-small Cell Lung Cancer
DrugCemiplimab
Regeneron Pharmaceuticals
Observational
500
Misterbianco, Florence, Udine, Rozzano, Orbassano, Pisa, Catania, Milan
2022-10-26
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
201
Catania, Genova, Milan, Naples, Orbassano, Pavia, Roma, Rozzano
2022-09-23
Active, closed
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
DrugRMC-6291
Revolution Medicines, Inc.
Phase 1
222
Milan, Naples, Orbassano, Pavia, Verona
2022-09-19
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT05271409Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
DrugSatralizumab
Hoffmann-La Roche
Phase 3
132
Pavia, Orbassano, Verona
2022-08-30
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 3
418
Bari, Bologna, Milan, Orbassano, Padova, Ravenna, Roma, Rome
2022-08-05
Recruiting
The Italian Transthyretin Amyloidosis Web-Network
NCT05444920ATTR Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
Observational
1,000
Legnano, Orbassano, Ancona, Bari, Bergamo, Brescia, Cagliari, Cosenza
2022-07-13
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 3
586
Bari, Chieti, Lucca, Milan, Orbassano, Parma, Perugia, Roma
2022-07-08
Recruiting
Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention
NCT06318559Cancer of Prostate
Fondazione del Piemonte per l'Oncologia
Not applicable
120
Candiolo, Orbassano
2022-06-29
Active, closed
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT05367440Metastatic Prostate Cancer
DrugsSaruparib·Zytiga·Xtandi·Apalutamide
AstraZeneca
Phase 1/2
174
Candiolo, Milan, Orbassano, Padova
2022-06-02
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,300
Gallarate, Ponderano, Rome, Genoa, Milan, Montichiari, Orbassano, Cefalรน
2022-05-03
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
DrugsBelzutifan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,800
Bari, Meldola, Rome, Milan, Orbassano, Florence, Arezzo, Bologna
2022-03-15
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
DrugsMonalizumab·Oleclumab·Durvalumab
AstraZeneca
Phase 3
1,051
Brescia, Florence, Lucca, Meldola, Orbassano, Parma, Pavia, Roma
2022-02-07
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ฮฑ- or ฮฒ-NTDT)
NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
194
Brindisi, Cagliari, Ferrara, Genova, Milan, Modena, Naples, Orbassano
2021-12-20
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
DrugSelpercatinib
Eli Lilly and Company
Phase 3
152
Bari, Milan, Rozzano, Naples, Orbassano, Padova
2021-12-20
Active, closed
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
NCT04982393Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals
Observational
207
Orbassano, Milan, Verona
2021-12-13
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
DrugsTeriflunomide·Remibrutinib
Novartis Pharmaceuticals
Phase 3
1,007
Brindisi, Foggia, Pozzilli, Messina, Modena, Pavia, Orbassano, Naples
2021-12-13
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (ฮฑ- or ฮฒ-TDT)
NCT04770779Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
258
Brindisi, Cagliari, Ferrara, Genova, Milan, Modena, Naples, Orbassano
2021-11-30
Recruiting
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
NCT04383119Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
DrugsTrabectedin·Gemcitabine
Italian Sarcoma Group
Phase 2
100
Bologna, Meldola, Prato, Rozzano, Aviano, Roma, Candiolo, Orbassano
2021-10-29
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin
AstraZeneca
Phase 3
454
Milan, Monza, Orbassano, Parma, Roma, Verona
2021-10-28
Rows per page Showing 1–100 of 153
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-italy/city/orbassano

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,830 studies in total at the last sync on 26 Sep 2026, 19:52 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 153 of those studies with a site in Orbassano.

How many clinical trials are recruiting in Orbassano?

67 of the 153 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:52 UTC sync. A further 4 have not yet opened recruitment, 82 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Orbassano), 153 studies
PhaseStudiesRecruitingShare
Phase 3812552.9%
Phase 2241015.7%
Observational171211.1%
Phase 1/21499.2%
Not applicable533.3%
Phase 1513.3%
Phase 2/3553.3%
Phase 4221.3%

Most active sponsors

Lead sponsors with the most studies (Orbassano)
Lead sponsorStudiesRecruiting
AstraZeneca288
Hoffmann-La Roche101
Merck Sharp & Dohme LLC72
Novartis Pharmaceuticals73
Pfizer75
Janssen Research & Development, LLC62
Daiichi Sankyo51
AbbVie43
Amgen41
Bristol-Myers Squibb43
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.